1. Introduction {#sec1-medicina-55-00026}
===============

Non-alcoholic fatty liver disease (NAFLD) is a range of hepatic disorders associated with fatty deposits in liver, which occur in the absence of alcohol consumption or alcohol abuse \[[@B1-medicina-55-00026]\]. NAFLD begins with an initial stage of fatty liver also known as hepatic steatosis (excessive fat loading in the hepatocytes). The progression from steatosis into cirrhosis of the liver due to inflammation and fibrosis results in irreversible damage to the liver \[[@B2-medicina-55-00026]\]. This condition is called non-alcoholic steatohepatitis (NASH)---a term first introduced by Ludwig et al. \[[@B3-medicina-55-00026]\] in clinical subjects with no history of alcohol consumption or abuse.

NAFLD is one of the most common chronic hepatic pathology. It has a worldwide distribution with an estimated prevalence of 25% for NAFLD and about 5% for NASH \[[@B4-medicina-55-00026]\]. The highest prevalence of NAFLD is observed in Western countries (17% to 46%) where it is the most common chronic liver disease (CLD) in adults with a high prevalence of NASH in the United States (16%). The World Gastroenterology Organisation suggests that the prevalence of NAFLD had doubled over the last 20 years. NAFLD and NASH are closely associated with diabetes and obesity, and together are considered one of the major causes of liver disease in Western countries \[[@B5-medicina-55-00026]\].

The pathophysiology of NASH was originally explained by the "two-hit" hypothesis \[[@B6-medicina-55-00026]\]. In this hypothesis, the first hit is responsible for producing steatosis (fat accumulation in liver), and the second hit is from oxidative stress causing lipid peroxidation. The pathogenesis and progression of NAFLD is complex, and was not completely explained by the "two hit" hypothesis. Currently, NASH is described by the "multiple hit" hypothesis \[[@B7-medicina-55-00026]\]. In this hypothesis, metabolic syndrome plays a major role due to insulin resistance and the inflammatory process mediated by interaction of different proteins and immune system. The components of the multiple "hits" are yet to be fully defined and they may vary in different patients. However, from available information, the "first hit" is caused by metabolic syndrome and insulin resistance, increased fat loading in hepatocytes leading to steatosis and liver injury. The accumulation of fat in the liver occur as a result of imbalance between the rate of influx and removal of triglycerides---a mechanism thought to protect hepatocytes from the lipotoxicity that may result from excessive influx of free fatty acids (FFAs) \[[@B8-medicina-55-00026]\]. Most of the FFAs stored as triglycerides originate from increased lipolysis in peripheral tissues as a result of adipose tissue insulin resistance (IR), attended by increased lipogenesis due to hyperinsulinemia and diet fat. The subsequent "hits" are responsible for the inflammation, fibrosis, apoptosis, oxidative stress (OS), and hepatic lipid peroxidation, mitochondrial dysfunction, release of adipokines and pro-inflammatory cytokines \[[@B7-medicina-55-00026]\] ([Figure 1](#medicina-55-00026-f001){ref-type="fig"}). Major histopathological features of NASH are steatosis, hepatocellular ballooning, lobular inflammation and in some cases, fibrosis \[[@B7-medicina-55-00026],[@B8-medicina-55-00026]\] and may progress into cirrhosis if left unchecked.

An understanding of the mechanism of OS, its regulation as well as its role in NAFLD is vital. This will provide researchers in the area of NAFLD/NASH with the best choice of OS/antioxidant (AO) biomarkers useful in pre-clinical investigations as well as in clinical diagnosis of NAFLD. Development of potent drugs in the treatment of NAFLD will also take the AO action required to counteract the OS associated with NAFLD into consideration. In this article, we review the role of oxidative stress in NAFLD and several AO and OS biomarkers that have been measured in pre-clinical and clinical evaluations.

2. Oxidative Stress {#sec2-medicina-55-00026}
===================

OS refers to an imbalance between the production of reactive species (RS) and AO defenses \[[@B9-medicina-55-00026]\]. A more encompassing definition describes it as "an imbalance between oxidants and AOs in favour of the oxidants, leading to a disruption of redox signalling and control and/or molecular damage" \[[@B9-medicina-55-00026],[@B10-medicina-55-00026]\]. RS (the oxidants) are chemically reactive species containing oxygen (reactive oxygen species, ROS), or nitrogen (reactive nitrogen species, RNS), etc. ([Table 1](#medicina-55-00026-t001){ref-type="table"}). ROS (which are the most extensively studied RS) are oxygen-containing molecules that exhibit higher chemical reactivity than oxygen (O~2~). Some ROS are free radicals (e.g., hydroxyl radical, superoxide radical, peroxyl radical etc.), others are non-radicals (e.g., hydrogen peroxide, hypochlorous acid, lipid peroxides etc.). RNS that are free radicals include nitric oxide, nitrogen dioxide etc., and those that are non-radicals include dinitrogen trioxide, peroxinitrite, etc. ([Table 1](#medicina-55-00026-t001){ref-type="table"}). OS has been classified according to severity as "eustress" (physiological oxidative stress) and "distress" (toxic oxidative burden which damages biomolecules) \[[@B10-medicina-55-00026],[@B11-medicina-55-00026]\]. In other words, low exposure to OS is useful for redox signalling, whereas high exposure results in disruption of redox signalling and causes damage to important biomolecules.

3. Oxidative Damage to Macromolecules {#sec3-medicina-55-00026}
=====================================

OS is associated with many diseases, especially those with an inflammatory mechanism \[[@B12-medicina-55-00026]\]. OS is known in several hepatic diseases with high levels of ROS and RNS, which is an important description of the severity and progression of the disease \[[@B13-medicina-55-00026],[@B14-medicina-55-00026]\]. ROS is constantly generated in the cell due to partial reduction of O~2~ or as a result of transfer of energy to O~2~. ROS can attack vital cell components like polyunsaturated fatty acids, proteins, and nucleic acids, and also carbohydrates in a few cases \[[@B15-medicina-55-00026],[@B16-medicina-55-00026],[@B17-medicina-55-00026]\]. They can disrupt membrane properties like fluidity and ion transport, cause loss of enzyme activity, disruption of the protein synthesis mechanism and induction of DNA damage, ultimately leading to cell death. Damage resulting from OS is often called "oxidative damage".

Oxidative damage to macromolecules (lipids, proteins, DNA etc.) results in formation of oxidative damage products ([Table 2](#medicina-55-00026-t002){ref-type="table"}), which are often measured as biomarkers of OS \[[@B18-medicina-55-00026],[@B19-medicina-55-00026],[@B20-medicina-55-00026],[@B21-medicina-55-00026]\]. Some of the most important oxidative damage products of lipids that are frequently measured includes malondialdehyde, lipid peroxides, 8-isoprostane, and 4-hydroxy-2-nonenal (4-HNE). Oxidation of protein can result in protein cross linkage, formation of protein carbonyls, and modification of amino acid. Important products of oxidative modification of amino acids that are frequently measured include 3-nitrotyrosine (a product of ROS-mediated nitration of tyrosine), 2-oxohistidine and hydroxyproline ([Table 2](#medicina-55-00026-t002){ref-type="table"}). DNA/RNA oxidation can cause single or double strand fragmentation or modification of bases or sugar. 8-Hydroxy-2′-deoxyguanosine (8-OH-dG) and 8-hydroxyguanine (8-OH-G) are the most commonly measured DNA/RNA damage products.

4. Regulation of OS {#sec4-medicina-55-00026}
===================

There are several mechanisms for the cellular regulation of OS, which are extremely important to the cell homeostasis. This is achieved through the antioxidant system, which can control the formation of ROS or RNS and also repair oxidative damage to cells. An antioxidant is any substance that can inhibit the oxidation of the cell components such as DNA, proteins and lipids. Several levels of antioxidative defense mechanism are used to prevent oxidative damage \[[@B22-medicina-55-00026],[@B23-medicina-55-00026]\]. The antioxidants can be derived from the diet or endogenously.

Endogenously derived antioxidants are classified as enzymic or non-enzymic antioxidants ([Table 3](#medicina-55-00026-t003){ref-type="table"}). Enzymic antioxidants of endogenous origin include superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione reductase, etc. SOD catalyse the dismutation of superoxide radical to hydrogen peroxide. The hydrogen peroxide formed in this process and other processes is detoxified by the action of catalase or glutathione peroxidase utilising the power of reduced glutathione (GSH). The latter becomes oxidised (to GSSG) and can be reduced back to GSH through the action of glutathione reductase. Some of the most physiologically vital non-enzymic antioxidants include ascorbate, glutathione, α-tocopherol (vitamin E), Ubiquinone, Thioredoxin (TRX), Bilirubin etc. These antioxidant substances are effective in the detoxification of free radicals and reactive species in the cell ([Table 3](#medicina-55-00026-t003){ref-type="table"}).

5. Sources and Role of OS in NAFLD/NASH {#sec5-medicina-55-00026}
=======================================

The sources of OS, as well as its role in NASH has been extensively reviewed by Koek et al. \[[@B24-medicina-55-00026]\] and Tariq et al. \[[@B25-medicina-55-00026]\]. OS results from excessive generation of reactive species (RS) or depletion of physiological redox homeostasis. RS (ROS or RNS) from the inflammatory response, the mitochondria, endoplasmic reticulum and peroxisomes also contribute to OS associated with NAFLD/NASH. Their sources and role in NAFLD/NASH are summarized in [Table 4](#medicina-55-00026-t004){ref-type="table"}.

The mitochondria are important contributors to the OS observed in NAFLD. In the hepatocytes, the mitochondria are not only involved in respiration but they participate in anaplerotic pathways including gluconeogenesis and other biosynthetic activities. During NAFLD, mitochondrial β-oxidation produces ROS that damage hepatocytes contributing to inflammation, and other responses \[[@B28-medicina-55-00026]\]. This increase in ROS production is related to increases in free fatty acid delivery in NAFLD. An increase in fatty acid induces oxidative metabolism, causing an increase in the level of OS and inflammation. The peroxisomal β-oxidation also contributes to the OS in NAFLD through generation of H~2~O~2~. Other sources of OS include the mitochondrial electron transport chain, the activities of microsomal cytochrome P450 enzymes, endoplasmic reticulum stress, the activity of xanthine oxidase and inflammatory responses. Their various contributions to OS in NAFLD are highlighted in [Table 4](#medicina-55-00026-t004){ref-type="table"}.

OS has been reported to play a significant role in the pathophysiological mechanism of NAFLD and NASH \[[@B44-medicina-55-00026],[@B45-medicina-55-00026]\]. Studies conducted in humans and animal models showed a strong association between the level of OS and the severity of NASH \[[@B26-medicina-55-00026],[@B46-medicina-55-00026]\]. Although clinical and experimental studies have reported higher levels of lipid peroxidation in NASH patients, the levels of circulating antioxidants have been less reported.

6. Antioxidant and OS Markers Measured in NAFLD/NASH {#sec6-medicina-55-00026}
====================================================

Several biomarkers of oxidative stress and antioxidants have been detected in clinical and experimental models of NAFLD and NASH. Most of these are assayed predominantly in the liver, serum, plasma, and in a few cases, in whole blood samples. Major assay procedures for the detection of these markers include colorimetry, ELISA, and immunohistochemistry.

6.1. Antioxidant Markers Measured in Clinical NAFLD/NASH {#sec6dot1-medicina-55-00026}
--------------------------------------------------------

At the clinical level, a number of antioxidants have been determined in the evaluation of NAFLD/NASH. They include the enzymic antioxidants: CAT, SOD, GPx, GR \[[@B47-medicina-55-00026],[@B48-medicina-55-00026],[@B49-medicina-55-00026],[@B50-medicina-55-00026],[@B51-medicina-55-00026],[@B52-medicina-55-00026],[@B53-medicina-55-00026],[@B54-medicina-55-00026]\], and non-enzymic antioxidants: ascorbic Acid, GSH, α-Tocopherol, Ubiquinone, Thioredoxin (TRX) and Bilirubin \[[@B48-medicina-55-00026],[@B49-medicina-55-00026],[@B50-medicina-55-00026],[@B51-medicina-55-00026],[@B52-medicina-55-00026],[@B53-medicina-55-00026],[@B54-medicina-55-00026],[@B55-medicina-55-00026],[@B56-medicina-55-00026],[@B57-medicina-55-00026],[@B58-medicina-55-00026]\] ([Table 5](#medicina-55-00026-t005){ref-type="table"}). In general, the activities/concentrations of these antioxidants tend to decrease in NAFLD/NASH patients with a few exceptions where they increased. These variations appear to be sample dependent: for instance, those determined in the liver samples of patient generally showed a decrease in their activities/levels in all the data reviewed. However, there are variations with respect to other samples such as blood, plasma and serum, where antioxidant levels tend to increase in most cases of NAFLD and NASH.

6.2. Oxidative Stress Markers Measured in Clinical NAFLD/NASH {#sec6dot2-medicina-55-00026}
-------------------------------------------------------------

Oxidative stress biomarkers that have been determined in clinical models of NAFLD include nitric oxide (NO), lipid damage products (lipid peroxides, TBARS (MDA), Hydroperoxides, 8-Isoprostane, 4-HNE), protein oxidation products (protein carbonyl, Nitrotyrosine), DNA oxidation product (8-OH-dG) and CYP2E1 ([Table 6](#medicina-55-00026-t006){ref-type="table"}). The concentrations/activities of these biomarkers increase generally in all the clinical data reviewed, except where the increase is not significant \[[@B52-medicina-55-00026]\] ([Table 6](#medicina-55-00026-t006){ref-type="table"}). The most frequently reported OS markers include the NO, MDA, 8-OH-dG and CYP2E1.

6.3. Antioxidant Markers Measured in Experimental Models of NAFLD/NASH {#sec6dot3-medicina-55-00026}
----------------------------------------------------------------------

Extensive data on antioxidants used to assess NAFLD/NASH in experimental models have been reviewed. They mainly cover the enzymic antioxidants: SOD, CAT, GPx, GR and the non-enzymic antioxidant---GSH in about five rodent models. In nearly all the experimental data reviewed, these antioxidants were measured in the liver and their activities decreased generally in most of the models (mainly NASH), except in a few cases as shown in [Table 7](#medicina-55-00026-t007){ref-type="table"}.

6.4. Oxidative Stress Markers Measured in Experimental Models of NAFLD/NASH {#sec6dot4-medicina-55-00026}
---------------------------------------------------------------------------

Oxidative stress biomarkers measured at experimental level of NAFLD/NASH include the reactive species (H~2~O~2~, nitrite/nitrate), lipid oxidation products (MDA, Lipid peroxide, 8-Isoprostanes, 4-HNE), protein damage products (Protein carbonyl, Dityrosine, Hydroxyproline, Nitrotyrosine), DNA damage product (8-OH-dG), and oxidative enzymes (CYP2E1, NADPH Oxidase, Xanthine Oxidase), as summarized in [Table 8](#medicina-55-00026-t008){ref-type="table"}.

The levels or activities of these biomarkers are found to consistently increase in all of the experimental models, except where the increases were not significant. In all the experimental models, MDA is the most measured oxidative stress biomarker as presented in [Table 8](#medicina-55-00026-t008){ref-type="table"}. Next to MDA is 4-HNE (another product of lipid oxidation), 8-OH-dG and CYP2E1. Others like H~2~O~2~, nitrite/nitrate, lipid peroxide, 8-Isoprostanes, Protein carbonyl, Dityrosine, Hydroxyproline, Nitrotyrosine), NADPH Oxidase and Xanthine Oxidase are not frequently measured. However, their levels/activities increase in a similar pattern to MDA, 8-OH-dG, 4-HNE, CYP2E1.

7. Conclusions {#sec7-medicina-55-00026}
==============

Oxidative stress plays an important role in the pathophysiology of NAFLD/NASH. Several markers of oxidative stress and antioxidants have been shown to be very useful in assessing the redox state in NAFLD/NASH. Among the oxidative stress biomarkers reviewed, TBARS, MDA, CYP2E1 and 4-HNE are unique; they are represented in both clinical and experimental measurements and they consistently increase. Antioxidants of interest in clinical and pre-clinical assessment of NAFLD/NASH include GSH, SOD, CAT, and GPx, which appear to be most reliably detected in liver samples.
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medicina-55-00026-t001_Table 1

###### 

Major ROS and RNS of physiological importance.

  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------
  **Major ROS**                              **Sources**                                                                                                                          
  Free Radicals                              Hydroxyl radical ($OH^{\bullet}$)                                                                                                    Decomposition of ONOO^−^ or, HOCl
  Superoxide radical ($O_{2}^{\bullet -}$)   Electron transport systems, and one-electron reduction of O~2~ by respiratory burst via the action of membrane bound NADPH oxidase   
  Peroxyl radical (ROO^•^)                   Produced in the Fenton reaction                                                                                                      
  Non-Radicals                               Hydrogen peroxide (H~2~O~2~)                                                                                                         Activated macrophages during inflammation
  Hypochlorous acid (HClO)                   Combined activities of NADPH oxidase and myeloperoxidase (MPO) in phagocytes                                                         
                                             Lipid peroxides (ROOH)                                                                                                               Formed from oxidation of polyunsaturated fatty acid via lipid-peroxyl radical reaction
  **Major RNS**                              **Sources**                                                                                                                          
  Free Radicals                              Nitric oxide (NO^•^)                                                                                                                 Nitric Oxide Synthase (NOS)
  Nitrogen dioxide ($NO_{2}^{\bullet}$)      Activated neutrophils                                                                                                                
  Non-radicals                               Dinitrogen trioxide (N~2~O~3~)                                                                                                       Produced in pathological conditions where (inducible nitric oxide (iNOS) is upregulated
  Peroxinitrite (ONOO^−^)                    Produced in pathological conditions where iNOS is upregulated                                                                        
  Nitrite ($NO_{2}^{-}$)                     Oxidation product from NO, formed during NOS activation in inflammatory diseases                                                     
  Nitryl ion ($NO_{2}^{+}$)                  Activated neutrophils                                                                                                                
  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------
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###### 

Some important oxidative damage products.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Macromolecule   Oxidative Damage                                                                  Damage Products
  --------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Lipids          Lipid oxidation/peroxidation                                                      Malondialdehyde (MDA)\
                                                                                                    Lipid peroxide, (lipid endoperoxides and lipid hydroperoxides)\
                                                                                                    8-Isoprostane\
                                                                                                    4-hydroxy-2-nonenal (4-HNE)

  Proteins        Protein Oxidation, protein cross linkage, Oxidative modification of amino acids   Protein carbonyl compounds,\
                                                                                                    3-Nitrotyrosine (product of ROS-mediated nitration of tyrosine), 2-oxohistidine, hydroxyproline etc.

  DNA             RNA/DNA fragmentation (single and double-strand breaks)\                          8-hydroxy-2′-deoxyguanosine (8-OH-dG), 8-hydroxyguanine (8-OH-G)
                  Modification of base, sugar                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Physiologically important antioxidants and their functions.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antioxidant Type               Antioxidant Name                                                                                                            Functions
  ------------------------------ --------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  Enzymic antioxidants           Superoxide dismutase (SOD)                                                                                                  Converts $O_{2}^{\bullet -}$ to H~2~O~2~ and O~2~

  Catalase (CAT)                 Converts H~2~O~2~ to 2H~2~O and O~2~                                                                                        

  Glutathione peroxidase (GPx)   Detoxifies H~2~O~2~ and Lipid peroxides using reduced glutathione (GSH) producing the oxidised form of glutathione (GSSG)   

  Glutathione reductase (GR)     Reduces GSSG to GSH                                                                                                         

  Non-enzymic antioxidants       Ascorbic Acid (AA)                                                                                                          Detoxifies Superoxide radical, Hydroxyl radical, and H~2~O~2~

  Reduced Glutathione (GSH)      Neutralizes Superoxide radical, Hydroxyl radical, and H~2~O~2~; co-substrate for glutathione peroxidase                     

  α-Tocopherol                   Detoxifies H~2~O~2~; protects against membrane lipid peroxidation (LPO)                                                     

  Ubiquinone                     Detoxifies Lipid peroxides                                                                                                  

                                 Thioredoxin (TRX)                                                                                                           General thiol redox control of protein activity via reversible disulfide formation

                                 Bilirubin                                                                                                                   Effective in quenching/scavenging\
                                                                                                                                                             secondary oxidants produced during OS
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Sources of oxidative stress in NAFLD/NASH.

  Source                                   Contribution to OS in NAFLD/NASH                                                                                                                     References
  ---------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  Mitochondrial metabolism (β-oxidation)   Production of ROS as a result of electron leakage during mitochondrial β-oxidation                                                                   \[[@B26-medicina-55-00026],[@B27-medicina-55-00026],[@B28-medicina-55-00026],[@B29-medicina-55-00026],[@B30-medicina-55-00026]\]
  Peroxisomal β-oxidation                  Generation of H~2~O~2~ during peroxisomal β-oxidation which is converted into hydroxyl radical contributing to OS                                    \[[@B31-medicina-55-00026]\]
  Mitochondrial electron transport chain   inhibition of electron transport chain by TNF-α and lipid peroxidation products                                                                      \[[@B32-medicina-55-00026],[@B33-medicina-55-00026]\]
  Microsomal Cytochrome P450 enzymes       ROS generation due to Increase in activity of cytochrome P4502E1 (CYP2E1) involved in lipooxygenation of longchain fatty acids                       \[[@B34-medicina-55-00026],[@B35-medicina-55-00026],[@B36-medicina-55-00026],[@B37-medicina-55-00026]\]
  Endoplasmic reticulum (ER) stress        Endoplasmic reticulum stress response, promotes OS via increased expression of CHOP (also called DDIT --DNA Damage Inducible Transcript-3 protein)   \[[@B38-medicina-55-00026]\]
  Xanthine Oxidase (XO)                    Increase in XO activity generates superoxide anions, due to induction by 4-HNE (a product of lipid peroxidation)                                     \[[@B39-medicina-55-00026],[@B40-medicina-55-00026]\]
  Inflammatory Response                    Abnormal inflammatory response mediated by gut microflora resulting in increase in pro-oxidants                                                      \[[@B41-medicina-55-00026],[@B42-medicina-55-00026],[@B43-medicina-55-00026]\]
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###### 

Antioxidant markers measured in clinical NAFLD/NASH.

  Antioxidant Marker      Sample      Level/Activity/Expression in Sample   Clinical Case                                           Reference(s)
  ----------------------- ----------- ------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------
  **SOD**                 Serum       Decreased, Increased (nsc)            NASH                                                    \[[@B47-medicina-55-00026],[@B48-medicina-55-00026],[@B49-medicina-55-00026]\]
  Serum/Liver             Decreased   NAFLD                                 \[[@B50-medicina-55-00026]\]                            
  Plasma                  Decreased   NAFLD                                 \[[@B51-medicina-55-00026]\]                            
  Blood                   Increased   NAFLD                                 \[[@B52-medicina-55-00026]\]                            
  Liver                   Decreased   NAFLD                                 \[[@B53-medicina-55-00026]\]                            
                          Blood       Increased                             NAFLD                                                   \[[@B54-medicina-55-00026]\]
  **CAT**                 Serum       Decreased, Increased (nsc)            NASH                                                    \[[@B47-medicina-55-00026],[@B48-medicina-55-00026]\]
  Plasma                  Decreased   NAFLD                                 \[[@B51-medicina-55-00026]\]                            
  Blood                   Increased   NAFLD                                 \[[@B52-medicina-55-00026]\]                            
  Liver                   Decreased   NAFLD                                 \[[@B53-medicina-55-00026]\]                            
                          Blood       Decreased                             NAFLD                                                   \[[@B54-medicina-55-00026]\]
  **GPx**                 Serum       Decreased                             NASH                                                    \[[@B48-medicina-55-00026],[@B49-medicina-55-00026]\]
  Blood                   Increased   NAFLD                                 \[[@B54-medicina-55-00026]\]                            
  Liver                   Decreased   NAFLD                                 \[[@B53-medicina-55-00026]\]                            
  **GR**                  Serum       Increased                             NASH                                                    \[[@B49-medicina-55-00026]\]
                          Blood       Increased                             NAFLD                                                   \[[@B54-medicina-55-00026]\]
  **Ascorbic Acid**       Serum       nsc                                   NASH                                                    \[[@B48-medicina-55-00026]\]
                          Serum       Decreased                             NAFLD                                                   \[[@B50-medicina-55-00026]\]
  **GSH**                 Serum       Increased                             NASH                                                    \[[@B49-medicina-55-00026]\]
  Blood                   Increased   NAFLD                                 \[[@B52-medicina-55-00026]\]                            
  Liver                   Decreased   NAFLD                                 \[[@B50-medicina-55-00026],[@B53-medicina-55-00026]\]   
                          Blood       Decreased                             NAFLD                                                   \[[@B54-medicina-55-00026]\]
  **α-Tocopherol**        Serum       Increased                             NASH                                                    \[[@B48-medicina-55-00026]\]
  Serum                   Decreased   NAFLD                                 \[[@B50-medicina-55-00026]\]                            
  **Ubiquinone**          Serum       Decreased                             NAFLD                                                   \[[@B51-medicina-55-00026]\]
  **Thioredoxin (TRX)**   Serum       Increased                             NAFLD                                                   \[[@B55-medicina-55-00026]\]
  **Bilirubin**           Serum       Decreased                             NASH                                                    \[[@B56-medicina-55-00026],[@B57-medicina-55-00026]\]
  Serum                   Decreased   NAFLD                                 \[[@B58-medicina-55-00026]\]                            

nsc: no significant change.
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###### 

Oxidative stress markers measured in clinical NAFLD/NASH.

  OS Marker          Sample      Level/Activity/Expression in Sample   Clinical Case                                           Reference(s)
  ------------------ ----------- ------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------
  Lipid peroxides    Plasma      Increased                             NASH                                                    \[[@B59-medicina-55-00026]\]
  NO^•^              Serum       Increased                             NASH                                                    \[[@B47-medicina-55-00026],[@B49-medicina-55-00026]\]
  Serum              Increased   NAFLD                                 \[[@B50-medicina-55-00026],[@B60-medicina-55-00026]\]   
  Blood              Increased   NAFLD                                 \[[@B52-medicina-55-00026]\]                            
  TBARS/MDA          Serum       Increased                             NAFLD                                                   \[[@B47-medicina-55-00026]\]
                     Serum       Increased                             NAFLD/NASH                                              \[[@B49-medicina-55-00026],[@B51-medicina-55-00026],[@B61-medicina-55-00026]\]
  Serum              Increased   NAFLD                                 \[[@B50-medicina-55-00026]\]                            
                     Blood       Increased                             NAFLD                                                   \[[@B54-medicina-55-00026]\]
  Hydroperoxides     liver       Increased                             NASH                                                    \[[@B62-medicina-55-00026]\]
  8-Isoprostane      Plasma      Increased                             NASH                                                    \[[@B48-medicina-55-00026]\]
  4-HNE              Liver       Increased                             NASH                                                    \[[@B63-medicina-55-00026]\]
  Protein carbonyl   Liver       Increased                             NAFLD                                                   \[[@B53-medicina-55-00026]\]
  Nitrotyrosine      Blood       nsc                                   NAFLD                                                   \[[@B52-medicina-55-00026]\]
  8-OH-dG            Liver       Increased                             NASH                                                    \[[@B63-medicina-55-00026],[@B64-medicina-55-00026]\]
  Liver              Increased   NAFLD                                 \[[@B65-medicina-55-00026]\]                            
  CYP2E1             Liver       Increased                             NASH                                                    \[[@B34-medicina-55-00026],[@B35-medicina-55-00026]\]
  Liver              nsc         Steatosis/NASH                        \[[@B66-medicina-55-00026]\]                            
  Liver              Increased   NAFLD                                 \[[@B53-medicina-55-00026]\]                            

nsc: no significant change.
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###### 

Antioxidant markers measured in experimental NAFLD/NASH.

  Antioxidant Marker   Sample      Level/Activity/Expression in Sample   Experimental Model    Experimental Specie            Reference(s)
  -------------------- ----------- ------------------------------------- --------------------- ------------------------------ ------------------------------
  SOD                  Liver       Decreased                             NASH (MCD)            Wistar Rats                    \[[@B67-medicina-55-00026]\]
  Liver                Increased   NASH (MCD)                            C57BL/6 Mice          \[[@B68-medicina-55-00026]\]   
  Liver                Increased   NASH (MCD)                            C57BL/6 mice          \[[@B69-medicina-55-00026]\]   
  Liver                Decreased   NASH (MCD)                            C57BL6/J mice         \[[@B70-medicina-55-00026]\]   
  Liver                Decreased   NASH (MCD)                            N-Mary rats           \[[@B71-medicina-55-00026]\]   
  Liver                Decreased   NAFLD (HFD)                           Mice                  \[[@B72-medicina-55-00026]\]   
  Liver                Decreased   NASH (HF)                             Kunming mice          \[[@B73-medicina-55-00026]\]   
  Liver                Increased   NAFLD (HFD)                           Rat                   \[[@B74-medicina-55-00026]\]   
  CAT                  Liver       Decreased                             NASH (MCD)            Wistar Rats                    \[[@B67-medicina-55-00026]\]
  Liver                Decreased   NASH (MCD)                            C57BL/6 Mice          \[[@B68-medicina-55-00026]\]   
  Liver                Increased   NASH (MCD)                            C57BL/6 mice          \[[@B69-medicina-55-00026]\]   
  Liver                Decreased   NASH (HCD)                            Wistar Rats           \[[@B75-medicina-55-00026]\]   
  Liver                Decreased   NAFLD (HFD)                           Sprague-Dawley rats   \[[@B74-medicina-55-00026]\]   
  GPx                  Liver       Decreased                             NASH (MCD)            Wistar Rats                    \[[@B67-medicina-55-00026]\]
  Liver                Increase    NASH (MCD)                            N-Mary rats           \[[@B71-medicina-55-00026]\]   
  Liver                Decreased   NAFLD (HFD)                           Mice                  \[[@B72-medicina-55-00026]\]   
  Liver                Decreased   NASH (HF)                             Kunming mice          \[[@B73-medicina-55-00026]\]   
  Liver                nsc         NAFLD (HFD)                           Sprague-Dawley rats   \[[@B74-medicina-55-00026]\]   
  GR                   Liver       Decreased                             NASH (MCD)            N-Mary rats                    \[[@B71-medicina-55-00026]\]
  GSH                  Liver       Decreased                             NASH (MCD)            Wistar Rat                     \[[@B67-medicina-55-00026]\]
  Liver                Decreased   NASH (MCD)                            N-Mary rats           \[[@B71-medicina-55-00026]\]   
  Liver                Decreased   NAFLD (HFD)                           Wistar Rats           \[[@B76-medicina-55-00026]\]   
  Liver                Decreased   NAFLD (HCD)                           Wistar Rats           \[[@B75-medicina-55-00026]\]   
  Liver/RBC            Increased   NASH (HF-MCD)                         Sprague-Dawley rats   \[[@B77-medicina-55-00026]\]   
  Liver                Decreased   NASH (MCD)                            Mice                  \[[@B78-medicina-55-00026]\]   

MCD: Methionine/Choline Deficient Diet; HF: High fructose Diet; HFD: High Fat Diet; HCD: High Cholesterol diet; HF-MCD: High fat- methionine choline deficient diet; nsc: no significant change.
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###### 

Oxidative stress markers measured in experimental NAFLD/NASH.

  OS Marker          Sample      Level/Activity/Expression in Sample   Experimental Model              Experimental Specie                                                              Reference(s)
  ------------------ ----------- ------------------------------------- ------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------
  H~2~O~2~           Liver       Increased                             NASH (MCD)                      C57BL/6J-mt^FVB/N^ mice                                                          \[[@B79-medicina-55-00026]\]
  Nitrite/nitrate    Liver       Nsc                                   NAFLD (HFD)                     Wistar Rats                                                                      \[[@B76-medicina-55-00026]\]
  TBARS (MDA)        Liver       Increased                             NASH                            Rat                                                                              \[[@B80-medicina-55-00026]\]
  Liver              Increased   NASH (MCD)                            C57BL/6 Mice                    \[[@B70-medicina-55-00026]\]                                                     
  Liver              Increased   Steatosis/NASH (HFD)                  Albino rats                     \[[@B81-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (MCD)                            C57BL/6 mice                    \[[@B69-medicina-55-00026]\]                                                     
  Liver              Decreased   NAFLD (HCD)                           Wistar Rats                     \[[@B75-medicina-55-00026]\]                                                     
  Liver              Increased   Steatosis (HFD/HSD)                   Wistar rats                     \[[@B82-medicina-55-00026]\]                                                     
  Liver              Increased   HF/HGD                                Wistar rats                     \[[@B83-medicina-55-00026]\]                                                     
  Liver              Increased   NAFLD (HFD)                           C57BL/6J mice                   \[[@B84-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (MCD)                            C57BL/6 mice                    \[[@B85-medicina-55-00026]\]                                                     
                     Liver       Increased                             NAFLD/NASH (CDAA diet)          Wistar Rats                                                                      \[[@B86-medicina-55-00026]\]
  Liver              Increased   NAFLD (HFD)                           Sprague-Dawley rats             \[[@B74-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (MCD)                            C57BL6/J mice                   \[[@B70-medicina-55-00026]\]                                                     
  Liver              Increased   NASH                                  Rat                             \[[@B80-medicina-55-00026]\]                                                     
  Liver              Increased   NAFLD (HFD)                           Wistar Rats                     \[[@B76-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (CDHF diet)                      Wistar Rats                     \[[@B87-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (MCD)                            N-Mary rats                     \[[@B71-medicina-55-00026]\]                                                     
  Liver              Increased   NAFLD (HFD)                           Mice                            \[[@B72-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (HF)                             Kunming mice                    \[[@B73-medicina-55-00026]\]                                                     
  Liver              Nsc         NASH (MCD)                            C57BL/6J-mt^FVB/N^ mice         \[[@B79-medicina-55-00026]\]                                                     
  Lipid peroxide     Liver       Increased                             NASH (MCD)                      Wistar Rat                                                                       \[[@B67-medicina-55-00026]\]
  8-Isoprostanes     Liver       Increased                             NASH (HFMCD)                    Sprague Dawley Rat                                                               \[[@B77-medicina-55-00026]\]
  4-HNE              Liver       Increased                             NASH (MCD)                      Wistar Rat                                                                       \[[@B67-medicina-55-00026]\]
  Liver              Increased   NASH                                  Rat                             \[[@B80-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (HFD)                            Sprague Dawley Rat              \[[@B88-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (CDHF diet)                      Wistar Rats                     \[[@B87-medicina-55-00026]\]                                                     
  Liver              Increased   NASH                                  leptin-deficient (ob/ob) mice   \[[@B89-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (HF-HSD)                         C57BL/6 J mice                  \[[@B90-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (MCD)                            C57BL6 mice                     \[[@B54-medicina-55-00026],[@B91-medicina-55-00026],[@B92-medicina-55-00026]\]   
  Protein carbonyl   Liver       Increased                             NASH (MCD)                      N-Mary rats                                                                      \[[@B93-medicina-55-00026]\]
  Nitrotyrosine      Liver       Increased                             NAFLD                           CYP2E1 transgenic (Tg) mice                                                      \[[@B93-medicina-55-00026]\]
  Dityrosine         Liver       Increased                             NAFLD (HFD)                     C57BL/6J mice                                                                    \[[@B84-medicina-55-00026]\]
  Hydroxyproline     Liver       Increased                             NAFLD/NASH (CDAA diet)          Wistar Rats                                                                      \[[@B86-medicina-55-00026]\]
  Liver              Increased   NASH (MCD/WD)                         C57BL6 mice                     \[[@B54-medicina-55-00026]\]                                                     
  8-OH-dG            Liver       Increased                             NASH (MCD)                      Wistar Rat                                                                       \[[@B69-medicina-55-00026]\]
  Liver              Decreased   NASH (HF-MCD)                         Sprague-Dawley rats             \[[@B79-medicina-55-00026]\]                                                     
  Liver              Increased   NAFLD (HFD)                           C57BL/6J mice                   \[[@B86-medicina-55-00026]\]                                                     
  CYP2E1             Liver       Increased                             NAFLD                           CYP2E1 transgenic (Tg) mice                                                      \[[@B92-medicina-55-00026],[@B93-medicina-55-00026]\]
  Liver              Increased   NASH (HFD)                            Sprague Dawley Rat              \[[@B88-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (HFD)                            Sprague Dawley Rat              \[[@B94-medicina-55-00026]\]                                                     
  Liver              Increased   Steatosis (HFD/HSD)                   Wistar rats                     \[[@B82-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (HFD)                            Sprague-Dawley rats             \[[@B95-medicina-55-00026]\]                                                     
  Liver              Increased   NASH (CDHF diet)                      Wistar rats                     \[[@B96-medicina-55-00026]\]                                                     
  NADPH Oxidase      liver       Increased                             NASH                            ob/ob mice                                                                       \[[@B89-medicina-55-00026]\]
  Xanthine Oxidase   Liver       Increased                             NAFLD (HFD)                     Sprague-Dawley rats                                                              \[[@B74-medicina-55-00026]\]

MCD: Methionine/Choline Deficient Diet; HF: High fructose Diet; HFD: High Fat Diet; HCD: High Cholesterol diet; HSD: High Sucrose diet; CDAA: Choline Deficient L-Amino Acid-defined; CDHF: Choline Deficient High Fat diet; HFMCD: High fat methionine choline deficient diet; HF-HSD: High fat-high sucrose diet; WD: Western diet; HF/HGD: High-Fructose/High-Glucose Diet; nsc: no significant change.
